Related references
Note: Only part of the references are listed.Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial
Meera S. Ramakrishnan et al.
JAMA OPHTHALMOLOGY (2020)
Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor
Rebecca Russ Soares et al.
OPHTHALMOLOGY RETINA (2020)
Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Anthony Obeid et al.
JAMA OPHTHALMOLOGY (2018)
Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials
Juan E. Grunwald et al.
OPHTHALMOLOGY (2017)
NATURAL COURSE OF PATIENTS DISCONTINUING TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND FACTORS ASSOCIATED WITH VISUAL PROGNOSIS
Jae Hui Kim et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2017)
Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular Degeneration Among Medicare Beneficiaries
Eleonora M. Lad et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2014)
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
Ursula Schmidt-Erfurth et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
REASONS FOR DISCONTINUATION OF INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Anagha Vaze et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2014)
The MANTA 1-year results: the anti-VEGF debate continues
Justis P. Ehlers
BRITISH JOURNAL OF OPHTHALMOLOGY (2013)
Introduction: Neovascular Age-Related Macular Degeneration Approaches for Improving Visual Acuity and Reducing the Burden of Care
Quan Dong Nguyen
OPHTHALMOLOGY (2013)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2012)
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Usha Chakravarthy et al.
OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study
Frank G. Holz et al.
OPHTHALMOLOGY (2011)
Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2011)
Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
P. Mitchell et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2010)
NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTS
Ninel Z. Gregori et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2010)
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
David M. Brown et al.
OPHTHALMOLOGY (2009)
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
Carl D. Regillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
